甲磺酸伊马替尼对慢性粒细胞白血病患者免疫功能的影响

Effect of Imatinib Mesylate on Immune Function in Patients with Chronic Myeloid Leukemia

目的探究甲磺酸伊马替尼对慢性粒细胞白血病患者免疫功能的影响。方法便利选取2015年10月—2019年10月菏泽市牡丹人民医院收治的62例慢性粒细胞白血病患者作为研究对象,按照投掷骰子的方式将患者平均分为对照组和观察组,对照组患者进行常规化疗治疗,观察组患者使用甲磺酸伊马替尼口服治疗。对比两组患者临床效果、发生的不良反应情况以及免疫功能发生的变化等情况。结果观察组患者治疗后缓解率为100.00%,对照组患者治疗后缓解率为70.96%,差异有统计学意义(χ^(2)=10.528,P=0.001)。治疗前两组患者的T细胞免疫功能中的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)指标对比,差异无统计学意义(P>0.05);治疗后观察组患者的CD3^(+)(1436.4±301.4)个/μl、CD4^(+)(788.4±155.9)个/μl、CD4^(+)/CD8^(+)为(1.61±0.47),均优于对照组,差异有统计学意义(P<0.05)。观察组患者非血液学不良反应发生率为45.16%,包括水肿10例(32.26%),皮疹1例(3.23%),腹痛腹泻2例(6.45%),恶心呕吐1例(3.23%),显著低于对照组不良反应发生率74.19%,差异有统计学意义(χ^(2)=5.429,P=0.020)。观察组患者中性粒细胞减少、血小板减少、贫血发生比例,均低于对照组,差异有统计学意义(χ^(2)=5.429、5.833、6.798,P<0.05)。结论慢性粒细胞白血病患者的临床治疗中使用甲磺酸伊马替尼,可有效保证治疗效果、改善患者的免疫功能,并且能够保证患者治疗期间的安全性,充分证明甲磺酸伊马替尼的临床应用价值较高。

Objective To explore the effect of imatinib mesylate on the immune function of patients with chronic myelogenous leukemia.Methods The 62 patients with chronic myeloid leukemia admitted to Heze Mudan People's Hospital from October 2015 to October 2019 were conveniently selected as the research subjects.The patients were divided into the control group and the observation group according to the method of throwing dice.Conventional chemotherapy was performed in the control group.Patients in the observation group were treated with imatinib mesylate orally.The clinical effects,adverse reactions and changes in immune function of the two groups of patients were compared.Results The remission rate of patients in the observation group was 100.00%,and the remission rate of patients in the control group was 70.96%,the difference was statistically significant(χ^(2)=10.528,P=0.001).Before treatment,there was no significant difference in the CD3^(+),CD4^(+),CD4^(+)/CD8^(+)indicators of the T cell immune function of the two groups of patients(P>0.05).After treatment,the observation group had CD3^(+)(1436.4±301.4)/μl,CD4^(+)(788.4±155.9)/μl,CD4^(+)/CD8^(+)was(1.61±0.47),which was better than the control group,the difference was statistically significant(P<0.05).The incidence of non-hematological adverse reactions in the observation group was 45.16%,including 10 cases of edema(32.26%),1 case(3.23%)of rash,2 cases of abdominal pain and diarrhea(6.45%),and 1 case of nausea and vomiting(3.23%),which was significantly lower the incidence of adverse reactions in the control group was 74.19%,the difference was statistically significant(χ^(2)=5.429,P=0.020).Neutropenia,thrombocytopenia,and the incidence of anemia in the observation group were lower than those in the control group,the difference was statistically significant(χ^(2)=5.429,5.833,6.798,P<0.05).Conclusion The use of imatinib mesylate in the clinical treatment of patients with chronic myelogenous leukemia can effectively ensure the therapeutic effect and improve the patient's immune function,and it can ensure the safety of patients during treatment,which fully proves the clinical application value of imatinib mesylate.